At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 7, 2026 at 08:00 ET
Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer vaccine EVX-01, with three-year clinical efficacy data expected in the second half of 2026. The trial has already shown a 75% Objective Response Rate and high durability, with 92% of patients still responding at two years and no relapses observed.
- Phase 2 trial extension completed; final three-year data expected in H2 2026
- Objective Response Rate of 75% (12 of 16 patients) with 4 complete responses
- 92% of patients maintained response at two-year follow-up; no relapses observed
- EVX-01 induced immune response in 100% of patients; 81% of targeted neoantigens generated potent T-cell responses
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access